Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nadroparin dosing in aneurysmal subarachnoid hemorrhage
NL-OMON54629Phase 2Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Feb 2022
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of nadroparin in subarachnoid hemorrhage (SAH) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: 30-day mortality. Started Feb 2022; status: recruiting.
02
Drugs
nadroparin
03
Conditions
subarachnoid hemorrhage (SAH)
Beyond the preview
Go deeper on NL-OMON54629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54629.